Prana moves forward on Alzheimer's treatment
Friday, 05 April, 2002
A treatment for Alzheimer's Disease is one step closer after the successful completion of a Phase II clinical trial by Prana Biotechnology for its drug PBT-1 (Iodochlorhydroxyquin).
The trial was performed on 32 patients. Half of the patients received the drug and half received a placebo, in a randomised double blind study. Full analysis of the results has not been completed.
Earlier studies in transgenic animals were published last year in the journal Neuron.
Prana's Executive Chairman, Geoffrey Kempler, said that as the current study was being prepared for publication, the company could not comment further on the results at this point in time.
Kempler said the company was pleased with the results, "It has given us a vote of confidence to keep moving forward."
Anti-inflammatory drug may help treat alcohol use disorder
A drug that is already FDA-approved for treating inflammatory conditions may help reduce both...
Osteoarthritis study uncovers new genetic links, drug targets
The genome-wide association study (GWAS) uncovered over 900 genetic associations, more than 500...
How brain cells are affected by Tourette syndrome
US researchers have conducted a cell-by-cell analysis of brain tissue from individuals with...
